Currently, Amylyx Pharmaceuticals Inc [AMLX] is trading at $6.41, up 27.69%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AMLX shares have gain 17.83% over the last week, with a monthly amount glided 19.59%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] stock has seen the most recent analyst activity on June 24, 2025, when Guggenheim initiated its Buy rating and assigned the stock a price target of $17. Previously, Citigroup started tracking the stock with Buy rating on June 17, 2025, and set its price target to $12. On May 30, 2025, TD Cowen initiated with a Buy rating. Mizuho upgraded its rating to a Outperform but stick to its price target of $7 on April 07, 2025. Robert W. Baird upgraded its rating to a Outperform and raised its price target to $11 on November 18, 2024. BofA Securities upgraded its rating to Buy for this stock on October 23, 2024, and upped its price target to $10. In a note dated March 18, 2024, Mizuho downgraded an Neutral rating on this stock and revised its target price from $32 to $4.
This stock has fluctuated between a low of $1.62 and a high of $7.27 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $10 within the next 12 months. Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] shares were valued at $6.41 at the most recent close of the market. An investor can expect a potential return of 56.01% based on the average AMLX price forecast.
Analyzing the AMLX fundamentals
Trailing Twelve Months sales for Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] were -1.27M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at 7.76% with Operating Profit Margin at 163.17%, Pretax Profit Margin comes in at 172.56%, and Net Profit Margin reading is 172.06%. To continue investigating profitability, this company’s Return on Assets is posted at -1.0, Equity is -1.06 and Total Capital is -1.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.58 points at the first support level, and at 4.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.97, and for the 2nd resistance point, it is at 7.53.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] is 12.05. Also, the Quick Ratio is 12.05, while the Cash Ratio stands at 3.33.
Transactions by insiders
Recent insider trading involved FRATES JAMES M, Chief Financial Officer, that happened on Mar 31 ’25 when 10896.0 shares were sold. Chief Medical Officer, Bedrosian Camille L completed a deal on Mar 31 ’25 to sell 12425.0 shares. Meanwhile, Chief Legal Officer Mazzariello Gina sold 9192.0 shares on Mar 31 ’25.
